IMV

Finger touching search engine bar
Biotech

Cancer biotech IMV hunts for a deal as its cash clock ticks down

Down to its last $21 million, IMV asked Stonegate to explore strategic alternatives amid concerns about its ability to continue as a going concern.
Nick Paul Taylor Mar 16, 2023 8:28am
layoffs layoff exit cut employees staff downsize workforce reduction

IMV drops 3rd of staff in refocus on lead oncology asset

Sep 15, 2022 9:45am
Fred Ors in lab with scientist

IMV's T-cell programming treatment keeps ovarian cancer at bay

Feb 25, 2020 11:08am